Articles Comments

Health and Diseases » Archive

Adding Imiquimod (Aldara) to standard cervical dysplasia treatment won’t prevent its recurrence

Immunomodulator medication which has the active ingredient of imiquimod (INN) has been approved by the FDA to treat premalignant of skin, cutaneous condition of subtype of basal cell carcinoma, and external genital warts with the side effects that should be considered. Due to genital warts, this drug may enhance the immune response, the researchers hypothesized that when adding this drug to current standard cervical dysplasia treatment (freezing, electrosurgery, or scalpels) may help from its recurring. However, after 2 years of randomized trial in 56 women with cervical dysplasia, which half of them also received topical imiquimod (Aldara) over roughly two weeks, the researchers said that imiquimod no help in preventing from recurrence. While 4 women in both of groups showed recurrence that involved at least one HPV type matching the type present at … Read entire article »

Filed under: Cervical Dysplasia

Iliac vein stenosis increases left-sided deep vein thrombosis (DVT) risk in women used combined oral contraceptive (COC)

Up to 25% of people in the healthy population have underlying stenosis for greater than 50% of the left common iliac vein. However, for women who have significant venous stenosis of the common iliac vein, who also use combined oral contraceptives (COC), they are at higher risk of deep vein thrombosis (DVT) than average risk. According to recent findings, every 1% increase in iliac vein stenosis (greater than 70%) increased the risk of DVT by 5%. And those who also use COC, the odds ratio of DVT increase to 5.46% for every 1% increase in stenosis. This conclusion based on evaluated 35 DVT’s women with computed tomography or magnetic resonance imaging and 35 age-matched control women who presented to the emergency room with abdominal pain. Reported in the American Journal of Obstetrics and Gynecology … Read entire article »

Filed under: Thrombosis

High dose antipsychotics Quetiapine no help in improving schizophrenia symptoms

Quetiapine is an antipsychotic drug for patients with schizophrenia or bipolar disorder. However, these drugs often used in high dose without adequate supporting data from the benefits of such action. While the use of quetiapine should be discontinued gradually and provide some potential side effects, the benefits of high doses also not useful in improving schizophrenia symptoms. In fact, the patient’s weight tend to rise. This conclusion is obtained after the researchers conducted a randomized trial for patients receiving approved-dose (800 mg/day) as a placebo group (43 patients) and a group with higher dose of 1,144 mg/day (88 patients). The improvement of schizophrenia symptoms measured with Positive and Negative Syndrome Scale (PANSS) score after treatment. Reported in the Journal of Clinical Psychiatry on June 14, 2011, the study authors, Dr. William G. Honer from the … Read entire article »

Filed under: Schizophrenia and Bipolar Disorder

Skin toxicities risk from hydroxyure (HU) treatment in patients with myleoproliferative neoplasm (MPN)

Patients with high risk of abnormal new growth of tissue or may be a tumour from their bone marrow disease (known as myeloproliferative neoplasm, MPN) are often and have long been receiving treatment with antineoplastic drug to suppresses the production of blood cell precursor in the bone marrow. However, this drug (known as hydroxyurea, HU) seem causing toxicities in the skin. This is based on studied among 993 patients registered between 1980 and 2009, including 614 (61.8) who received HU from four different hematologic centers for Philadelphia chromosome-negative MPN patients. According to the study authors, Dr. Roberto Latagliata from La Sapienza University in Rome and colleagues said that their findings showed the severe and frequent of skin toxicity during HU treatment no longer categorized as ‘mild’ like it was believed for decades from … Read entire article »

Filed under: Myeloproliferative

New warning label for smoking cessation medication of varenicline (Cantix, Pfizer) from FDA

New warning label for safety and efficacy of smoking-cessation medication of varenicline marketed as Cantix from Pfizer company just announced by the U.S. Food and Drug Administration (FDA). The announcement states that varenicline is effective in stopping the smoking habit in patients with cardiovascular disease, but also linked to small increased risk of cardiovascular adverse events. This new label based on the result of previous studies that showed potential risk of cardiovascular adverse events when taken by patients with cardiovascular disease to quit smoking. The study also advised the doctors to consider the risks and benefits of the drug before prescribing to their patients. Current announcement by agency also provide information about the use of varenicline in patients with chronic obstructive pulmonary disease (CPOD). Although varenicline effective than placebo in helping patients to quit … Read entire article »

Filed under: Smoking Cessation

Concomitant of roflumilast with long-acting beta-2 agonists in patients with severe COPD

Roflumilast is a drug to treat lung inflammation and has been suggested used concomitantly with long-acting beta-2 agonist (LABA) in patients with severe chronic obstructive pulmonary disease (COPD). To see the effects of those concomitant and its benefit to the patients at higher risk of exacerbation, therefore the researchers from South Africa studied two data from earlier 12-month trials that suggested roflumilast improved lung function and reduced exacerbation in severe to very severe of COPD patients who were allowed to receive short-acting beta-2 agonists (SABAs) and who continued treatment with either short-acting muscarinic antagonists (SAMAs) or LABAs. Reported in the European Respiratory Journal on July 4, 2011, the study authors, Dr. Eric D. Bateman at the University of Cape Town Lung Institute, South Africa, and colleagues in Europe said that their findings … Read entire article »

Filed under: COPD

Esophageal cancer risk significantly showed in patients with mild or absent GERD symptoms than severe levels

Identification of Barrett Esophageus (BE) is one of suggesting target during screening for esophageal cancer risk in patients with severe gastroesophageal reflux disease (GERD). However, according to recent study, a significant risk of esophageal cancer are actually in patients who have mild or absent GERD symptoms. That’s a conclusion from the study of 769 patients with GERD underwent primary screening endoscopy from November 1, 2004, through June 7, 2007, at the hospital of University of Pittsburgh in Pittsburgh, Pennsylvania. According to the study authors, Katie S. Nason, MD, MPH, from the Division of Thoracic and Foregut Surgery at those institution, and colleagues, increasing the prevalence of BE, dysplasia, or cancer undergoing primary endoscopic screening are not associated with severe GERD symptoms. Based on their study, from 122 patients detected with esophageal cancer, the odds … Read entire article »

Filed under: Digestive system

Adding progesterone or synthetic progestins to esterogen effects in menopausal women

Some evidences has suggested that adding progesterone or synthetic progestins can weaken the protective effects of estrogen on memory function in postmenopausal women, even harm risk. In a new comparison research of estrogen alone, or with micronized progesterone, or with medroxyprogesterone acetate (MPA), the researchers found that that adding MPA to estrogen significantly but modestly decreased delayed verbal memory scores compared with others. However, based on the Digit Span Backward test, the performance in estrogen plus MPA groups showed improved, whereas no change in other groups. The performance also improved over time in all groups from a test of visual-spatial sequencing, but not to other test of spatial ability or verbal memory. Overall, the researchers concluded that adding progestins to estrogen may alter cognitive benefits from estrogen in menopausal women and whether micronized progesterone … Read entire article »

Filed under: Menopause

Treatment of gastroesophageal reflux (GER) increase survival rate for idiopathic pulmonary fibrosis (IPF) patients

Since pulmonary fibrosis patients often experience with gastroesophageal reflux (GER), the researchers found that treating this disease could increase the survival rate among those patients. Whether GER as a consequences of having idiopathic pulmonary fibrosis (IPF) or treating IPF may increase survival rate, at least current study found that taking GER medications can reduce fibrosis score (using radiologic) compared with non-GER medications group. This conclusion based on anaylzed data of 204 patients (mean age was 70) with idiopathic pulmonary fibrosis at two centers over a 7-year period. Reported in the American Journal of Respiratory and Critical Care Medicine on June 23, 2011, the team found that GER medication was significantly increase survival rate with a mortality hazard ratio of 0.47 (p=0.03) and 14% of fibrosis score vs 19% in non-GER medications. However, the study … Read entire article »

Filed under: Pulmonary Fibrosis

Injection of NSAID better than corticosteroid in patients with shoulder impingement syndrome

While previous research has indicated that nonsteroidal anti-inflammatory drug (NSAID) injection is useful in the treatment of impingement syndrome at the shoulder, but until recently corticosteroid injection is common treatment for this disorder, despite it is associated with adverse effects of tendon rupture, depression of the skin because loss of tissue, and changes to articular cartilage. Due to the risk of corticosteroid injection and positive results of previous NSAIDs’ research, the researchers initiated the study to compare the effectiveness between those treatments. Presented at 2011 annual meeting of the American Orthopaedic Society for Sport Medicine (AOSSM), held on July 10, 2011, the lead of study authors who presented the findings, Kyong Su Min, MD, from the Madigaan Healthcare System in Tacoma, said that both of those treatments have a good response. However, … Read entire article »

Filed under: Syndrome